Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England.
Melissa Ruth GannonDavid DodwellAjay AggarwalMin Hae ParkKatie MillerKieran HorganKaren ClementsJibby MedinaDavid Alan CromwellPublished in: British journal of cancer (2023)
Use of NICE-recommended drugs for IBC in routine care is variable, with lowest use among women aged 70+ years. Improving access to effective treatments is an important step in improving outcomes.
Keyphrases
- quality improvement
- polycystic ovary syndrome
- healthcare
- breast cancer risk
- pregnancy outcomes
- primary care
- cervical cancer screening
- prostate cancer
- rectal cancer
- insulin resistance
- type diabetes
- stem cells
- radical prostatectomy
- pregnant women
- pain management
- bone marrow
- drug induced
- metabolic syndrome
- mesenchymal stem cells
- chronic pain
- affordable care act